Disclosure of promising top-line data from a phase II dose-optimization trial evaluating the therapeutic vaccine GEN-003 in genital herpes boosted shares of Genocea Biosciences Inc. (NASDAQ:GNCA) 8.8 percent Wednesday, aided by a price target hike from Piper Jaffray & Co.